Antimicrobial evaluation of quaternary ammonium polyethyleneimine nanoparticles against clinical isolates of pathogenic bacteria. Issue 6 (1st December 2015)

• Record Type: Journal Article
• Authors: Ortega, Agustín; Farah, Shady; Tranque, Pedro; Ocaña, Ana V.; Nam‐Cha, Syong H.; Beyth, Nurit; Gómez‐Roldán, Carmen; Pérez‐Tanoira, Ramón; Domb, Abraham J.; Pérez‐Martínez, Francisco C.; Pérez‐Martínez, Juan
• Is Part Of: IET nanobiotechnology. Volume 9:Issue 6(2015)
• Page Start: 342
• Page End: 348
• Publication Date: 2015-12-01
• Subjects: microorganisms -- diseases -- antibacterial activity -- ammonium compounds -- nanoparticles -- nanomedicine -- inhibitors -- toxicology -- cellular biophysics -- nanofabrication; antimicrobial evaluation -- quaternary ammonium polyethyleneimine nanoparticles -- clinical isolates -- pathogenic bacteria strains -- peritonitis -- disease -- alternative therapeutic compounds -- antibiotic‐resistant bacteria -- Streptococcus viridans -- Stenotrophomonas maltophilia -- Escherichia coli -- minimal inhibitory concentration -- minimal bactericidal concentration -- bactericidal assays -- annexin V‐propidium iodide toxicity assays -- cell cultures -- growth curve assays -- inhibited bacterial growth -- potential therapeutic value -- gram‐negative bacteria; Biotechnology -- Periodicals; Nanotechnology -- Periodicals; 660.6
• DOI: 10.1049/iet-nbt.2014.0078
• Languages: English
• ISSNs: 1751-8741

Abstract

Abstract : Peritonitis is a disease caused by bacterial strains that have become increasingly resistant to many antibiotics. The development of alternative therapeutic compounds is the focus of extensive research, so novel nanoparticles (NPs) with activity against antibiotic‐resistant bacteria should be developed. In this study, the antibacterial activity of quaternary ammonium polyethyleneimine (QA‐PEI) NPs was evaluated against Streptococcus viridans, Stenotrophomonas maltophilia and Escherichia coli . To appraise the antibacterial activity, minimal inhibitory concentration (MIC), minimal bactericidal concentration and bactericidal assays were utilised with different concentrations (1.56–100 µg/ml) of QA‐PEI NPs. Moreover, 3‐[4, 5‐dimethylthiazol‐2‐yl]‐2, 5‐diphenyl tetrazolium bromide (MTT) and annexin V/propidium iodide toxicity assays were performed in cell cultures. MICs for S. maltophilia and E. coli isolates were 12.5 and 25 µg/ml, respectively, whereas the MIC for S. viridans was 100 µg/ml. Furthermore, the growth curve assays revealed that these QA‐PEI NPs at a concentration of 12.5 µg/ml significantly inhibited bacterial growth for the bacterial isolates studied. On the other hand, QA‐PEI NPs lacked significant toxicity for cells when used at concentrations up to 50 μg/ml for 48 h. The present findings reveal the potential therapeutic value of this QA‐PEI NPs as alternative antibacterial agents for peritonitis, especially against Gram‐negative bacteria.